MARKET

PGNX

PGNX

Progenics Pharm
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.690
+0.285
+8.37%
After Hours: 3.690 0 0.00% 16:00 04/09 EDT
OPEN
3.470
PREV CLOSE
3.405
HIGH
3.710
LOW
3.390
VOLUME
583.36K
TURNOVER
--
52 WEEK HIGH
6.37
52 WEEK LOW
1.890
MARKET CAP
319.54M
P/E (TTM)
-4.6021
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average PGNX stock price target is 6.75 with a high estimate of 7.00 and a low estimate of 6.50.

EPS

PGNX News

More
  • Merger Arbitrage Mondays - 7 Deals Close But Spreads Remain Wide
  • Seeking Alpha - Article · 2d ago
  • The Daily Biotech Pulse: Setback For DBV In Peanut Allergy Patch Review, Roche Starts Coronavirus Test Shipment, Regeneron Aims For 'Cocktail' COVID-19 Treatment
  • Benzinga · 03/17 15:38
  • Progenics Pharmaceuticals EPS beats by $0.12, beats on revenue
  • seekingalpha · 03/13 17:37
  • PROGENICS PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2019 FINANCIAL RESULTS
  • GlobeNewswire · 03/13 13:30

Industry

Biotechnology & Medical Research
+1.63%
Pharmaceuticals & Medical Research
+0.82%

Hot Stocks

Symbol
Price
%Change

About PGNX

Progenics Pharmaceuticals, Inc. is engaged in developing medicines and other products for targeting and treating cancer. The Company's pipeline includes therapeutic agents designed to target cancer (AZEDRA and 1095); prostate specific membrane antigen (PSMA)-targeted imaging agents for prostate cancer (1404 and PyL), and imaging analysis tools. It also includes commercial product, RELISTOR (methylnaltrexone bromide) for opioid-induced constipation. AZEDRA is a radiotherapeutic product candidate in development as a treatment for malignant and/or recurrent pheochromocytoma and paraganglioma, rare tumors found in the adrenal glands and outside of the adrenal glands, respectively. RELISTOR is a treatment for opioid induced constipation. PyL is a clinical-stage, fluorinated PSMA-targeted Positron Emission Topography (PET) imaging agent for prostate cancer. PSMA TTC is a thorium-227 labeled PSMA-targeted antibody therapeutic.
More

Webull offers kinds of Progenics Pharmaceuticals, Inc. stock information, including NASDAQ:PGNX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PGNX stock news, and many more online research tools to help you make informed decisions.